skip to Main Content

Bob is our Executive Vice President, Research, and Chief Technology Officer. He is a co-founding scientist of Maverick and has led the design of the proprietary COBRA™ platform for the development of conditionally active T cell engaging therapies for solid tumor indications.  Bob is a leader in the emerging field of T cell engagement therapeutics. Bob joined Maverick at its formation when it was spun out from Harpoon Therapeutics as its Senior Vice President, Research Discovery. In 2010 Bob founded Full Spectrum Genetics (FSG) to develop a novel, high throughput mutation profiling system to create detailed structural maps of protein binding sites. In 2015 FSG developed the S4 system for rapidly creating affinity matured antibodies from selected single substitution CDR libraries. Later that year Harpoon Therapeutics licensed that technology and Bob joined Harpoon to help engineer novel T cell engagement therapeutics.

From 1999 to 2010 Bob led the New Technologies and Antibody Engineering groups at Eos and then PDL Biopharma. During this time his group humanized numerous therapeutic antibodies and developed a new antibody engineering platform called PxP. After completing his postdoctoral studies at Genentech in 1989, Bob was one of the founding scientists of Cell Genesys, Inc. where he was responsible for setting up systems to create genetic knockouts in primary human cells. He later became the Director of the Massively Parallel Signature Sequencing (MPSS) project at Lynx Therapeutics and his group was responsible for setting up the first next generation sequencing platform.

Bob received his B.A. in Biology from the University of California at San Diego in 1981 and his Ph.D. in Genetics from Stanford University in 1987.

Back To Top